CMMB
Chemomab Therapeutics Ltd.
1W: -20.5%
1M: +2.6%
3M: -18.0%
YTD: -11.2%
1Y: -67.9%
3Y: -73.3%
5Y: -99.2%
$1.59
+0.02 (+1.27%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$9.8M
52W Range1.35-5.88
Volume63,831
Avg Volume83,055
Beta0.54
Dividend—
Analyst Ratings
Company Info
CEOAdi Mor George
Employees20
SectorHealthcare
IndustryBiotechnology
IPO Date2019-02-12
Websitechemomab.com
Building 7
Tel Aviv 6158002
IL
Tel Aviv 6158002
IL
972 77 331 0156
About Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
Latest News
Chemomab Therapeutics reports Q4 results
Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update
Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update
Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) Sees Significant Growth in Short Interest
Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Quigley Jill M. | A-Award | 6,857 | $1.71 | 2023-06-16 |
| Darvish Nissim | A-Award | 20,572 | $1.70 | 2023-06-14 |
| Fatal Sigal | A-Award | 102,860 | $1.70 | 2023-06-14 |
| Fatal Sigal | 0 | — | 2023-06-01 | |
| Fatal Sigal | 29,400 | $2.11 | 2023-06-01 |